Peripheral arterial disease: a cardiovascular time bomb

Jill Belch, Gerry Stansby, Cliff Shearman, Julie Brittenden, Shiela Dugdill, Gerry Fowkes, Sarah Jarvis, Terrie McCann, Andrew Mimnagh, David Monkman, Jonathan Morrell

    Research output: Contribution to journalComment/debate

    10 Citations (Scopus)

    Abstract

    Peripheral arterial disease (PAD) is a reliable marker of future vascular disease and is a substantial public health issue. In Europe and North America, 27 million people are estimated to have PAD, and in the UK around 100,000 people are diagnosed every year. People with PAD are six times more likely to die from cardiovascular disease within 10 years than people without PAD. Evidence suggests that aggressive risk factor management will prevent many premature deaths and associated morbidity. Therefore, it is vital to identify patients and initiate effective management strategies swiftly. However, whilst 40% of PAD patients have symptomatic disease ranging from intermittent claudication to critical limb ischaemia, around 60% are asymptomatic. As a result of the low rates of detection PAD is underdiagnosed and undertreated in the UK. The gravity of the problem has prompted the formation of professional bodies to address this situation through the development of national clinical guidelines. Indeed, with the focus of general practitioners' work covered by the quality and outcomes framework in the General Medical Services (GMS) contract, many consider that the inclusion of PAD in the GMS contract is critical to raising awareness and improving the management of PAD in primary care.
    Original languageEnglish
    Pages (from-to)236-239
    Number of pages3
    JournalBritish Journal of Diabetes and Vascular Disease
    Volume7
    Issue number5
    DOIs
    Publication statusPublished - 2007

    Fingerprint

    Peripheral Arterial Disease
    Contract Services
    Intermittent Claudication
    Premature Mortality
    Risk Management
    Gravitation
    North America
    Vascular Diseases
    General Practitioners
    Primary Health Care
    Cardiovascular Diseases
    Ischemia
    Extremities
    Public Health
    Guidelines
    Morbidity

    Cite this

    Belch, J., Stansby, G., Shearman, C., Brittenden, J., Dugdill, S., Fowkes, G., ... Morrell, J. (2007). Peripheral arterial disease: a cardiovascular time bomb. British Journal of Diabetes and Vascular Disease, 7(5), 236-239. https://doi.org/10.1177/14746514070070050701
    Belch, Jill ; Stansby, Gerry ; Shearman, Cliff ; Brittenden, Julie ; Dugdill, Shiela ; Fowkes, Gerry ; Jarvis, Sarah ; McCann, Terrie ; Mimnagh, Andrew ; Monkman, David ; Morrell, Jonathan. / Peripheral arterial disease : a cardiovascular time bomb. In: British Journal of Diabetes and Vascular Disease. 2007 ; Vol. 7, No. 5. pp. 236-239.
    @article{64550b370bc3475a804aad46fbacdf81,
    title = "Peripheral arterial disease: a cardiovascular time bomb",
    abstract = "Peripheral arterial disease (PAD) is a reliable marker of future vascular disease and is a substantial public health issue. In Europe and North America, 27 million people are estimated to have PAD, and in the UK around 100,000 people are diagnosed every year. People with PAD are six times more likely to die from cardiovascular disease within 10 years than people without PAD. Evidence suggests that aggressive risk factor management will prevent many premature deaths and associated morbidity. Therefore, it is vital to identify patients and initiate effective management strategies swiftly. However, whilst 40{\%} of PAD patients have symptomatic disease ranging from intermittent claudication to critical limb ischaemia, around 60{\%} are asymptomatic. As a result of the low rates of detection PAD is underdiagnosed and undertreated in the UK. The gravity of the problem has prompted the formation of professional bodies to address this situation through the development of national clinical guidelines. Indeed, with the focus of general practitioners' work covered by the quality and outcomes framework in the General Medical Services (GMS) contract, many consider that the inclusion of PAD in the GMS contract is critical to raising awareness and improving the management of PAD in primary care.",
    author = "Jill Belch and Gerry Stansby and Cliff Shearman and Julie Brittenden and Shiela Dugdill and Gerry Fowkes and Sarah Jarvis and Terrie McCann and Andrew Mimnagh and David Monkman and Jonathan Morrell",
    year = "2007",
    doi = "10.1177/14746514070070050701",
    language = "English",
    volume = "7",
    pages = "236--239",
    journal = "British Journal of Diabetes and Vascular Disease",
    issn = "1474-6514",
    publisher = "SAGE Publications",
    number = "5",

    }

    Belch, J, Stansby, G, Shearman, C, Brittenden, J, Dugdill, S, Fowkes, G, Jarvis, S, McCann, T, Mimnagh, A, Monkman, D & Morrell, J 2007, 'Peripheral arterial disease: a cardiovascular time bomb', British Journal of Diabetes and Vascular Disease, vol. 7, no. 5, pp. 236-239. https://doi.org/10.1177/14746514070070050701

    Peripheral arterial disease : a cardiovascular time bomb. / Belch, Jill; Stansby, Gerry; Shearman, Cliff; Brittenden, Julie; Dugdill, Shiela; Fowkes, Gerry; Jarvis, Sarah; McCann, Terrie; Mimnagh, Andrew; Monkman, David; Morrell, Jonathan.

    In: British Journal of Diabetes and Vascular Disease, Vol. 7, No. 5, 2007, p. 236-239.

    Research output: Contribution to journalComment/debate

    TY - JOUR

    T1 - Peripheral arterial disease

    T2 - a cardiovascular time bomb

    AU - Belch, Jill

    AU - Stansby, Gerry

    AU - Shearman, Cliff

    AU - Brittenden, Julie

    AU - Dugdill, Shiela

    AU - Fowkes, Gerry

    AU - Jarvis, Sarah

    AU - McCann, Terrie

    AU - Mimnagh, Andrew

    AU - Monkman, David

    AU - Morrell, Jonathan

    PY - 2007

    Y1 - 2007

    N2 - Peripheral arterial disease (PAD) is a reliable marker of future vascular disease and is a substantial public health issue. In Europe and North America, 27 million people are estimated to have PAD, and in the UK around 100,000 people are diagnosed every year. People with PAD are six times more likely to die from cardiovascular disease within 10 years than people without PAD. Evidence suggests that aggressive risk factor management will prevent many premature deaths and associated morbidity. Therefore, it is vital to identify patients and initiate effective management strategies swiftly. However, whilst 40% of PAD patients have symptomatic disease ranging from intermittent claudication to critical limb ischaemia, around 60% are asymptomatic. As a result of the low rates of detection PAD is underdiagnosed and undertreated in the UK. The gravity of the problem has prompted the formation of professional bodies to address this situation through the development of national clinical guidelines. Indeed, with the focus of general practitioners' work covered by the quality and outcomes framework in the General Medical Services (GMS) contract, many consider that the inclusion of PAD in the GMS contract is critical to raising awareness and improving the management of PAD in primary care.

    AB - Peripheral arterial disease (PAD) is a reliable marker of future vascular disease and is a substantial public health issue. In Europe and North America, 27 million people are estimated to have PAD, and in the UK around 100,000 people are diagnosed every year. People with PAD are six times more likely to die from cardiovascular disease within 10 years than people without PAD. Evidence suggests that aggressive risk factor management will prevent many premature deaths and associated morbidity. Therefore, it is vital to identify patients and initiate effective management strategies swiftly. However, whilst 40% of PAD patients have symptomatic disease ranging from intermittent claudication to critical limb ischaemia, around 60% are asymptomatic. As a result of the low rates of detection PAD is underdiagnosed and undertreated in the UK. The gravity of the problem has prompted the formation of professional bodies to address this situation through the development of national clinical guidelines. Indeed, with the focus of general practitioners' work covered by the quality and outcomes framework in the General Medical Services (GMS) contract, many consider that the inclusion of PAD in the GMS contract is critical to raising awareness and improving the management of PAD in primary care.

    U2 - 10.1177/14746514070070050701

    DO - 10.1177/14746514070070050701

    M3 - Comment/debate

    VL - 7

    SP - 236

    EP - 239

    JO - British Journal of Diabetes and Vascular Disease

    JF - British Journal of Diabetes and Vascular Disease

    SN - 1474-6514

    IS - 5

    ER -